A trial record update on August 6, 2026 shows a pre-approval expanded access program for retatrutide, also known as LY3437943. The listing, titled "Pre-approval Expanded Access of Retatrutide (LY3437943)," carries the status AVAILABLE on ClinicalTrials.gov under identifier NCT07629401.
The record does not list a phase designation, consistent with its classification as an expanded access program rather than a standard interventional trial phase. Expanded access listings are intended to describe pathways for access outside of standard trial enrollment, and this update reflects only that the program status is currently AVAILABLE as of the listed date.
No outcomes, efficacy data, or safety findings are included in this record. The listing does not state eligibility criteria, enrollment numbers, or program duration. This brief reports only the status and title as reflected in the ClinicalTrials.gov entry as of the update date.
Readers can consult the official ClinicalTrials.gov record for further procedural details on this expanded access program. For additional background on retatrutide, see the compound overview linked with this brief.